KARPAS 1718

Oncology research

Human splenic lymphoma

KARPAS 1718 is derived from the peripheral blood of a patient diagnosed with transformed splenic lymphoma with villous lymphocytes

STR-PCR Data: Amelogenin: X,Y
CSF1PO: 11,13
D13S317: 8,13
D16S539: 11,13
D5S818: 11,12
D7S820: 8
THO1: 6
TPOX: 8,11
vWA: 14

Maintain cultures between 3-9 x 10⁵ cells/ml; 5% CO₂; 37°C. Thaw ampoule and perform a cell count, spin out the DMSO and resuspend in an appropriate volume of media to give a cell concentration of 4-5 x 10⁵ cells/ml. Viability may be poor on resuscitation and may decrease further within the first 48 hours, the culture may appear non-viable at this time. Clusters of cells will eventually appear but this could take 1-2 weeks, during this time large media changes are not recommended. It may take 2-3 weeks for vigorous growth to be established. At subculture perform a cell count and maintain cultures between 3-9 x 105 cells/ml, 5% CO₂, 37°c. For cryopreservation of KARPAS 1718, freeze at approximately 2 x 107 cells/ml in 90% FBS + 10% DMSO.

RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS)

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). Use of this product by commercial organizations may require a license agreement. Commercial customers will be contacted by cellscreening@merckgroup.com to provide further information after the order request is submitted. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.